share_log

EF Hutton Initiates Coverage On Coeptis Therapeutics With Buy Rating, Announces Price Target of $6

Benzinga Real-time News ·  Dec 13, 2022 06:38

EF Hutton analyst Michael King initiates coverage on Coeptis Therapeutics (NASDAQ:COEP) with a Buy rating and announces Price Target of $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment